AOD-9604 research guide

AOD-9604 in Japan — Sourcing Guide

Research-grade AOD-9604 sourcing guide for Japan. COA verification, vendor selection, and handling protocols.

Browse Regions Order AOD-9604 →

Japan Guide to AOD-9604 Research

Japan's regulatory environment for research peptides is consistent with most international jurisdictions — AOD-9604 is unscheduled in the majority of countries, and importation for legitimate research is broadly allowed. The practical sourcing landscape for Japan researchers is dominated by international vendors, concentrated in the US, Europe, and China — with varying quality standards across suppliers. For Japan researchers, the key priority is independently verifying COA data rather than relying on any national regulatory oversight. This guide covers the relevant Japan considerations for AOD-9604 alongside the analytical verification criteria that are consistent globally.

Understanding AOD-9604 — Evidence Overview

The regulatory status of GHS compounds like AOD-9604 varies by country and has evolved over time. Some compounds in this class have been or are being investigated as pharmaceutical candidates — Sermorelin has been used clinically in GH deficiency treatment, and MK-677 (Ibutamoren) is an oral GHS that has undergone phase 2 clinical trials. This mixed pharmaceutical-research status means Japan researchers should verify the specific regulatory status of AOD-9604 in their jurisdiction, as compounds with pharmaceutical development history may face different import regulations than pure research compounds. Japan's health authority website is the definitive source for current status.

Order AOD-9604 in Japan
COA-verified · Ships to Japan · International tracking
Order Now →

Browse by Region

Top Cities in Japan

Finding Quality AOD-9604 in Japan

The practical buying guide for AOD-9604 in Japan: identify a shortlist of vendors with established community standing and proven Japan delivery records. The COA verification step that Japan researchers frequently overlook is checking that the certificate batch reference matches the actual vial you receive — a COA is only meaningful when it is batch-matched to the specific product you have. Express shipping options from most major vendors reduce delivery timelines to 3-7 days — customs delays are the primary source of variability, typically accounting for 2-5 extra days in most cases. The community research step is often undervalued by first-time purchasers — it is the highest-value time investment in the sourcing process for Japan researchers.

AOD-9604 Safety & Research Protocols

The most significant quality-related safety concern for AOD-9604 is endotoxin from inadequate quality control — verify endotoxin testing is included in your batch COA prior to any in-vivo use. Research compound handling standards for AOD-9604 apply regardless of location in Japan: store lyophilised material at −20°C, reconstitute with bacteriostatic water in a sterile working environment, and keep reconstituted product refrigerated for no more than 30 days. Regulatory compliance for AOD-9604 research in Japan involves understanding both applicable import rules and institutional research oversight that apply to your specific research context.

Order AOD-9604 — ships to Japan
COA-verified · International shipping · All compounds research grade
Order Now →

Frequently Asked Questions

What is the clinical trial history of AOD-9604?

AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.

How does AOD-9604 differ from growth hormone?

AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.

What is AOD-9604?

AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.